Prediction of UA/SOD Ratio as a Biomarker of Oxidative Stress in Atrial Fibrillation

Atrial Fibrillation Clinical Trial

Official title:

Prediction of UA/SOD Ratio as a Biomarker of Oxidative Stress in Atrial Fibrillation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06119802
• Other study ID #: YXLL-KY-2023(044)
• Status: Recruiting
• Start date: January 1, 2022
• Est. completion date: April 30, 2024

Study information

• Verified date: November 2023
• Source: Qianfoshan Hospital
• Contact: Yinglong Hou, PhD
• Phone: 13791120810
• Email: yujiao61[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To clarify the predictive effects of uric acid and superoxide dismutase as biomarkers of oxidative stress on atrial fibrillation, and to provide greater value for the diagnosis and prediction of atrial fibrillation. It provides a new idea for the prevention and treatment of atrial fibrillation.

Description:

In recent years, a growing number of reports have shown the importance of oxidative stress in the pathophysiological mechanism of AF. During oxidative stress, there is an imbalance between the production of pro-oxidant reactive species and the antioxidant defenses of the cell, and excessive oxidation leads to oxidative damage and cell death. Redox processes can lead to atrial fibrosis and cardiac remodeling , suggesting that strategies to address myocardial oxidative stress may constitute a reasonable approach for the treatment of AF. However, few studies have reported the relationship between comprehensive oxidative stress-related biomarkers and AF. The purpose of this study was to illuminate the relationship of several blood markers of oxidative stress with AF and to provide new clues for the prevention and treatment of AF.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10000
• Est. completion date: April 30, 2024
• Est. primary completion date: October 31, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria: This retrospective study enrolled all hospitalized patients from January 2018 to December 2020 at the Department of Cardiology in The First Affiliated Hospital of Shandong First Medical University. The diagnosis of AF was based on 12-lead electrocardiography (ECG) or 24-hour Holter monitoring, and classification was based on the published 2020 ESC guidelines for the diagnosis and management of AF.

Exclusion Criteria:

1. acute heart failure and acute myocardial infarction;

2. severe liver or kidney dysfunction (with aspartate aminotransferase or alanine aminotransferase levels three times higher than normal and estimated glomerular filtration rate <30 ml/ (min*1.73 m2));

3. malignant tumors;

4. missing data of laboratory indicators at baseline.

Related Conditions & MeSH terms

• Atrial Fibrillation
• Hyperuricemia

Intervention

Diagnostic Test:
• atrial fibrillation
ECG of atrial fibrillation last more than 30 seconds.

Locations

Country	Name	City	State
China	Shandong provincal Qianfoshan hospital	Jinan	Shandong

Sponsors (1)

Lead Sponsor	Collaborator
Yinglong Hou

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Uric acid/SOD ratio is associated with atrial fibrillation	Uric acid/SOD ratio is associated with atrial fibrillation	3 years